Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety
Graphical abstract
Section snippets
Acknowledgements
We thank NIDA (RO1 DA023947) and Seaside Therapeutics (VUMC33842) for their support of our programs in the development of noncompetitive antagonist of mGlu5. We also thank Tammy S. Santomango for technical contributions with the protein binding assays.
References and notes (41)
- et al.
Neuropharmacology
(1999)et al.Annu. Rev. Pharmacol. Toxicol.
(1997) - et al.
Eur. J. Pharmacol.
(2006)et al.Eur. J. Pharmacol.
(2005)et al.Neuropsychopharmacology
(2004)et al.Neuropharmacology
(2004)et al.J. Pharmacol. Exp. Ther.
(2000) - et al.
Sci. Transl. Med.
(2012)et al.Neuropsychopharmacology
(2010) - et al.
J. Pharmacol. Exp. Ther.
(2009)et al.Behav. Brain Res.
(2009)et al.Psychopharmacology
(2008)et al.Neuropsychopharmacology
(2006)et al.J. Pharmacol. Exp. Ther.
(2005)et al.Psychopharmacology
(2005)et al.Eur. J. Pharmacol.
(2004) - et al.
Psychopharmacology
(2010) - et al.
Neuropsychopharmacology
(2009) - et al.
Br. J. Pharmacol.
(2010)et al.J. Neurosci.
(2009)et al.Psychopharmacology
(2009)et al.Neuropharmacology
(2008)et al.Drug Alcohol Depend.
(2006) - et al.
Sci. Transl. Med.
(2011)et al.J. Med. Genet.
(2009) - et al.
Neurology
(2013)et al.Mov. Disord.
(2011) - et al.
ACS Chem. Neurosci.
(2013)et al.Bioorg. Med. Chem. Lett.
(2009)et al.Bioorg. Med. Chem. Lett.
(2009)et al.Bioorg. Med. Chem. Lett.
(2009)
Bioorg. Med. Chem. Lett.
ACS Chem. Neurosci.
Bioorg. Med. Chem. Lett.
Chem. Med. Chem.
NeuroRx®
J. Pharmacol. Toxicol. Methods
J. Pharm. Biomed. Anal.
Mol. Pharmacol.
Br. J. Pharmacol.
Eur. J. Pharmacol.
J. Med. Chem.
Nat. Rev. Drug Disc.
ACS Chem. Biol.
Basic Clin. Pharmacol. Toxicol.
Pharmacol. Ther.
Expert Opin. Ther. Pat.
ACS Chem. Neurosci.
Curr. Top. Med. Chem.
Curr. Opin. Drug Discov. Dev.
Curr. Opin. Drug Discov. Dev.
Neuropharmacology
Cited by (27)
Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology
2019, NeuropharmacologyCitation Excerpt :VU0409106, VU0366058 and VU0366248 represent chemotypes distinct from MPEP – namely the aryl ether series (Felts et al., 2013), 5-cyanopyrimides (Mueller et al., 2012) and 3-cyano-5-fluoro-N-arylbenzamides (Felts et al., 2010) respectively. Previous reports indicate VU0409106 and VU0366058 are full NAMs of glutamate-mediated iCa2+ mobilization, while VU0366248 is a partial NAM (Felts et al., 2013; Gregory et al., 2012). Fenobam and dipraglurant were included to represent mGlu5 NAMs that have progressed to clinical trials (Pecknold et al., 1982; Tison et al., 2016).
Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5
2019, Bioorganic and Medicinal Chemistry LettersDiscovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5
2018, Bioorganic and Medicinal Chemistry LettersDiscovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5
2017, Bioorganic and Medicinal Chemistry LettersComputer-aided design of negative allosteric modulators of metabotropic glutamate receptor 5 (mGluR5): Comparative molecular field analysis of aryl ether derivatives
2016, Bioorganic and Medicinal Chemistry Letters